OCS

Oculis Holding AG

A clinical-stage biopharmaceutical company developing new treatments for eye and neuro-ophthalmic diseases, working on easy-to-use eye drops to address conditions like optic neuritis. Its roots stretch to a group founded in Reykjavik, Iceland, in 2003, and it is now based in Zug, Switzerland. The name comes from the Latin word "oculus," meaning eye, and the company listed on the Nasdaq stock exchange in 2023 after merging with a European biotech acquisition company.

No proxy statement recorded.